Outcomes Research in Review
Annual U.S. incidence rates of invasive and in situ melanoma steadily climbed to a new high of 178,560 cases in 2018.
Rates in Utah and Vermont should have the rest of the country between them in 2018.
New findings regarding the T-cell repertoire in NSCLC patients could have implications for the use of TIL therapy, checkpoint blockade, and more...
Health plans are under fire for the hidden conflicts of interest in their clinical pathway panels.